Paper31396148
Prospective Assessment of No Evidence of Disease Activity-4 Status in Early Disease Stages of Multiple Sclerosis in Routine Clinical Practice.
Guevara C and 11 others. Front Neurol, 2019. Cited by 15 papers, by iCite.
Cite this record
ConductScience Library. Prospective Assessment of No Evidence of Disease Activity-4 Status in Early Disease Stages of Multiple Sclerosis in Routine Clinical Practice. Papers, record 31396148. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31396148
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Prospective Assessment of No Evidence of Disease Activity-4 Status in Early Disease Stages of Multiple Sclerosis in Routine Clinical Practice.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References33
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10506095 | The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. | Brain | 1999 | https://conductscience.org/library/papers/10506095 | PubMed |
| 2 | 11351200 | Normalized accurate measurement of longitudinal brain change. | J Comput Assist Tomogr | 2001 | https://conductscience.org/library/papers/11351200 | PubMed |
| 3 | 12372740 | Brain atrophy in mild or moderate traumatic brain injury: a longitudinal quantitative analysis. | AJNR Am J Neuroradiol | 2002 | https://conductscience.org/library/papers/12372740 | PubMed |
| 4 | 12482100 | Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. | Neuroimage | 2002 | https://conductscience.org/library/papers/12482100 | PubMed |
| 5 | 15501092 | Advances in functional and structural MR image analysis and implementation as FSL. | Neuroimage | 2004 | https://conductscience.org/library/papers/15501092 | PubMed |
| 6 | 15911795 | Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects. | Neurology | 2005 | https://conductscience.org/library/papers/15911795 | PubMed |
| 7 | 17178742 | Manifestations of early brain recovery associated with abstinence from alcoholism. | Brain | 2007 | https://conductscience.org/library/papers/17178742 | PubMed |
| 8 | 17940723 | Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: sample size estimates. | J Neurol | 2007 | https://conductscience.org/library/papers/17940723 | PubMed |
| 9 | 18064587 | Effects of acute dehydration on brain morphology in healthy humans. | Hum Brain Mapp | 2009 | https://conductscience.org/library/papers/18064587 | PubMed |
| 10 | 19168190 | Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study. | J Neurol Sci | 2009 | https://conductscience.org/library/papers/19168190 | PubMed |
| 11 | 20089952 | A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. | N Engl J Med | 2010 | https://conductscience.org/library/papers/20089952 | PubMed |
| 12 | 20483380 | Evaluation of automated techniques for the quantification of grey matter atrophy in patients with multiple sclerosis. | Neuroimage | 2010 | https://conductscience.org/library/papers/20483380 | PubMed |
| 13 | 21387374 | Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. | Ann Neurol | 2011 | https://conductscience.org/library/papers/21387374 | PubMed |
| 14 | 2259435 | Towards quantitative measurements of relaxation times and other parameters in the brain. | Neuroradiology | 1990 | https://conductscience.org/library/papers/2259435 | PubMed |
| 15 | 22799620 | Brief International Cognitive Assessment for MS (BICAMS): international standards for validation. | BMC Neurol | 2012 | https://conductscience.org/library/papers/22799620 | PubMed |
| 16 | 23153407 | Measurement and clinical effect of grey matter pathology in multiple sclerosis. | Lancet Neurol | 2012 | https://conductscience.org/library/papers/23153407 | PubMed |
| 17 | 24446248 | Clinical relevance of brain volume measures in multiple sclerosis. | CNS Drugs | 2014 | https://conductscience.org/library/papers/24446248 | PubMed |
| 18 | 25531931 | Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. | JAMA Neurol | 2015 | https://conductscience.org/library/papers/25531931 | PubMed |
| 19 | 25877624 | Editors' welcome and a working definition for a multiple sclerosis cure. | Mult Scler Relat Disord | 2013 | https://conductscience.org/library/papers/25877624 | PubMed |
| 20 | 25904813 | Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. | J Neurol Neurosurg Psychiatry | 2016 | https://conductscience.org/library/papers/25904813 | PubMed |
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39379875 | Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies. | BMC Neurol | 2024 | https://conductscience.org/library/papers/39379875 | PubMed |
| 39251843 | Assessing disease progression and treatment response in progressive multiple sclerosis. | Nat Rev Neurol | 2024 | https://conductscience.org/library/papers/39251843 | PubMed |
| 38347079 | Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder. | Sci Rep | 2024 | https://conductscience.org/library/papers/38347079 | PubMed |
| 37864717 | Identification and management of subclinical disease activity in early multiple sclerosis: a review. | J Neurol | 2024 | https://conductscience.org/library/papers/37864717 | PubMed |
| 37819598 | No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review]. | Neurol Ther | 2023 | https://conductscience.org/library/papers/37819598 | PubMed |
| 37448960 | Magnetic resonance imaging and ultrasound elastography in the context of preclinical pharmacological research: significance for the 3R principles. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37448960 | PubMed |
| 36901807 | Recent Progress in the Identification of Early Transition Biomarkers from Relapsing-Remitting to Progressive Multiple Sclerosis. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36901807 | PubMed |
| 36114980 | Unmet needs and gaps in the identification of secondary progression in multiple sclerosis: a Southern Italy healthcare professionals' perspective. | Neurol Sci | 2023 | https://conductscience.org/library/papers/36114980 | PubMed |
| 35159972 | Brain Volume Loss Can Occur at the Rate of Normal Aging in Patients with Multiple Sclerosis Who Are Free from Disease Activity. | J Clin Med | 2022 | https://conductscience.org/library/papers/35159972 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/31396148
GET https://conductscience.org/api/papers/v1/31396148/references?page=2